Mar 2, 2019

Differences and similarities in the effects of ibrutinib and acalabrutinib on platelet functions

Haematologica
Jennifer SeriesBernard Payrastre

Abstract

While efficient at treating B-cell malignancies, Bruton tyrosine kinase (BTK) inhibitors are consistently reported to increase the risk of bleeding. Analyzing platelet aggregation response to collagen in platelet-rich plasma allowed us to identify two groups in the healthy population characterized by low or high sensitivity to ibrutinib in vitro Inhibition of drug efflux pumps induced a shift from ibrutinib low-sensitive platelets to high-sensitive ones. At a clinically relevant dose, acalabrutinib, a second-generation BTK inhibitor, did not affect maximal collagen-induced platelet aggregation in the ibrutinib low-sensitive group but did inhibit aggregation in a small fraction of the ibrutinib high-sensitive group. Consistently, acalabrutinib delayed aggregation, particularly in the ibrutinib high-sensitive group. In chronic lymphocytic leukemia patients, acalabrutinib inhibited maximal platelet aggregation only in the ibrutinib high-sensitive group. Acalabrutinib inhibited collagen-induced tyrosine-753 phosphorylation of phospholipase Cγ2 in both groups, but, in contrast to ibrutinib, did not affect Src-family kinases. Acalabrutinib affected thrombus growth under flow only in the ibrutinib high-sensitive group and potentiated ...Continue Reading

  • References
  • Citations3

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations3

Citations

Mentioned in this Paper

Src-Family Kinases
Cyclooxygenase 2
Replacement Therapy
Platelet Function
Drug Efflux
Protein Aggregation, Pathological
Phospholipase C
Malignant Neoplasms
Enzyme Inhibitors
Hemorrhage

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.